Meta-Chlorophenylpiperazine

Meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the piperazine chemical class. It was initially developed in the 1970s by the pharmaceutical company Pfizer during the process of creating a new antidepressant medication. mCPP has been used as an experimental tool in animal and human studies to understand the role of serotonin receptors in the brain.

Pharmacology

mCPP acts as a serotonin receptor agonist, meaning it binds to and activates these receptors. It has a high affinity for the 5-HT2C receptor subtype, and a moderate affinity for the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, and 5-HT3 receptor subtypes. mCPP also has a weak affinity for the dopamine and norepinephrine receptors.

Effects

The effects of mCPP can vary greatly depending on the individual and the dose taken. Some common effects include anxiety, panic attacks, dizziness, nausea, and headaches. At higher doses, mCPP can cause hallucinations, delusions, and psychosis.

Legal Status

The legal status of mCPP varies by country. In the United States, it is not controlled under the Controlled Substances Act, but it is considered a Schedule I substance under the Analog Act if intended for human consumption. In the United Kingdom, mCPP is a Class C drug under the Misuse of Drugs Act.

See Also

• Piperazine
• Serotonin receptor
• Psychoactive drug

‎